Phathom Pharmaceuticals stock draws a Moderate Buy consensus

Published on 10/07/2026 at 00:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Phathom Pharmaceuticals stock carries a Moderate Buy view from nine analysts on October 6, 2026, with earnings set for October 29. Q2 net revenue reached USD 74.3 million, up 88 percent year over year.

PHAT, US71722W1071, Illustration mit AI erstellt.

Phathom Pharmaceuticals (ISIN US71722W1071) stock carries a Moderate Buy consensus from nine analysts and an average 12-month target of USD 21.25 as of October 6, 2026, according to MarketBeat. The next quarterly report is scheduled for October 29, 2026.

Target stands above the quote

Phathom Pharmaceuticals was last at USD 6.8860 on Nasdaq on October 2, 2026, after trading as low as USD 6.84 against a 52-week high of USD 18.31. The average analyst target lies 208.6 percent above that price, a gap that reflects the market's sharp reassessment of the commercial and clinical outlook.

The same consensus includes six Buy ratings, one Strong Buy, one Hold and one Sell. The stock's market capitalization was USD 563.5 million on October 2, 2026, while its 50-day moving average stood at USD 8.77.

Revenue growth meets lower guidance

Phathom Pharmaceuticals reported Q2 2026 net revenue of USD 74.3 million, up 88 percent from Q2 2025 and 27 percent from Q1 2026. Operating expenses were USD 63.1 million, down 33 percent from the year-earlier quarter.

The counterweight is the full-year outlook. Stocktwits reported on July 30, 2026, that Phathom lowered 2026 net revenue guidance to USD 310 million to USD 325 million from USD 320 million to USD 345 million. That narrower range places execution around VOQUEZNA at the center of the investment case.

VOQUEZNA enters another trial

On September 29, 2026, Phathom Pharmaceuticals announced patient screening for the registrational Phase 3 pHalcon-NERD-302 study of as-needed VOQUEZNA in non-erosive GERD. The trial is designed for 500 adults at 80 U.S. sites, with topline results expected in the first quarter of 2028.

The program gives VOQUEZNA a future label-expansion path beyond its existing gastrointestinal indications. For the stock, the near-term test remains whether prescription growth can offset the lower 2026 revenue range before the October report.

Phathom Pharmaceuticals stock stays below its yearly range

Phathom Pharmaceuticals was last at USD 6.8860 on Nasdaq on October 2, 2026, with a 52-week range of USD 6.64 to USD 18.31. The next scheduled report is October 29, 2026.